Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.
The Severe hypertriglyceridemia (SHTG) synopsis provides a high level overview of the care standards employed for this Clinical Pathway.
Algorithms associated with this Clinical Pathway:
Inclusion and exclusion criteria
- SHTG related to:
- Diabetes and insulin resistance.
- Hematologic-oncologic processes.
- Renal disease.
- TPN use.
Committee members involved in the development of this Clinical Pathway:
- E Maris Wee, MD | Department of Endocrinology – Fellow| Committee chair
- M. Feldt, DO | Department of Endocrinology | Committee chair mentor
- R. McDonough, DO |Department of Endocrinology | Committee member
- L. Fullenkamp, MD, JD | Department of Hospital Medicine | Committee member
- N. Ibrahimi, MD | Department of Gastroenterology | Committee member
- A. Wagner, DO | Department of Critical Care Medicine | Committee member
- L. Enlow, PharmD | Department of Pharmacy | Committee member
- D. Porter, MSN, RN | 6 Henson Tower Nursing Director | Committee member
- K. Berg, MD, FAAP | Department of Evidence Based Practice and Hospital Medicine
- A. Melanson, OTD, OTR/L | Department of Evidence Based Practice
- J. A. Bartlett, PhD, RN | Department of Evidence Based Practice
- Finalized date: October 2021
- Next expected revision date: October 2024
Concerns with content:
If you have any question regarding this content, or identify a broken link, please email firstname.lastname@example.org.